• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

New EPAD paper in Frontiers in Big Data

2021-08-10News

A new article from the EPAD consortium entitled “Disease modelling of cognitive outcomes and biomarkers in the European Prevention of Alzheimer’s Dementia Longitudinal Cohort” has recently been published in the journal Frontiers in Big Data.

Abstract: A key challenge for the secondary prevention of Alzheimer’s dementia is the need to identify individuals early on in the disease process through sensitive cognitive tests and biomarkers. The European Prevention of Alzheimer’s Dementia (EPAD) consortium recruited participants into a longitudinal cohort study with the aim of building a readiness cohort for a proof-of-concept clinical trial and also to generate a rich longitudinal data-set for disease modelling. Data have been collected on a wide range of measurements including cognitive outcomes, neuroimaging, cerebrospinal fluid biomarkers, genetics and other clinical and environmental risk factors, and are available for 1828 eligible participants at baseline, 1567 at six months, 1188 at one-year follow-up, 383 at two years, and 89 participants at three-year follow-up visit. We novelly apply state-of-the-art longitudinal modelling and risk stratification approaches to these data in order to characterise disease progression and biological heterogeneity within the cohort. Specifically, we use longitudinal class-specific mixed effects models to characterise the different clinical disease trajectories and a semi-supervised Bayesian clustering approach to explore whether participants can be stratified into homogeneous subgroups that have different patterns of cognitive functioning evolution, while also having subgroup-specific profiles in terms of baseline biomarkers and longitudinal rate of change in biomarkers.

Congratulations to the authors James Howlett, Steven M. Hill, Craig W. Ritchie and Brian D. Tom! You can find the paper here: https://doi.org/10.3389/fdata.2021.676168

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
ADDI NeuroToolKit Data Hackathon
2022-05-17
The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
2022-05-09
First national follow-on study to EPAD LCS launches
2022-04-07
The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
2022-03-10
New paper on the affordances of clinical research participation
2022-01-14
ADDI celebrates one year of achievements
2021-11-17
Latest News
  • ADDI NeuroToolKit Data Hackathon
    2022-05-17
  • The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
    2022-05-09
  • First national follow-on study to EPAD LCS launches
    2022-04-07
  • The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
    2022-03-10
  • New paper on the affordances of clinical research participation
    2022-01-14
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

Registration is now open for the upcoming #NeuroToolKit Data Hackathon! Join fellow experts and investigate biomarkers in #Alzheimers disease. You'll work with @IMI_EPAD datasets by utilizing @AlzData resources. For more information: ep-ad.org/addi-neurotool… twitter.com/IMI_EPAD/statu…

reply retweet favorite
6:56 am · 2022-05-18
Twitter
EPAD
EPAD
@IMI_EPAD

📢 Four abstracts with @IMI_EPAD data have been accepted for #AAIC22, including 3 posters & 1 oral presentation! Looking forward to meeting you in San Diego! @LuigiLorenzini1 @GregorySarah @fpmaragall @amsterdamumc @CenDemPrevent twitter.com/alzassociation…

reply retweet favorite
10:45 am · 2022-04-28
Twitter
EPAD
EPAD
@IMI_EPAD

The @IMI_EPAD Research Participant Panel has been established to give participants an active role in influencing the design, conduct and reporting of research. Want to know more? Watch this recording. #31AEC @AlzheimerEurope @IMI2_NEURONET @CenDemPrevent youtu.be/GObdDorTOE0?t=…

reply retweet favorite
6:42 am · 2022-04-20
Twitter
EPAD
EPAD
@IMI_EPAD

Listen to @GregorySarah from @CenDemPrevent talking about the associations between stressful life events, #Alzheimer's disease biomarkers and cognition in the @IMI_EPAD Longitudinal Cohort Study at the @AlzheimerEurope conference #31AEC. youtu.be/loZSphK4s9g

reply retweet favorite
9:45 am · 2022-04-11
Twitter
EPAD
EPAD
@IMI_EPAD

We are delighted to announce that the first study participant for the @IMI_EPAD Scotland study was seen today! It is the first national initiative to have started study recruitment. @craig_ritchie68 @CenDemPrevent For more info, visit our website⤵️ ep-ad.org/first-national… pic.twitter.com/4Z46mokA88

reply retweet favorite
12:44 pm · 2022-04-07
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT